Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in prog ...

Core Viewpoint - Zelluna ASA, a company focused on allogeneic T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment, announced its first quarter 2025 results, highlighting significant advancements in its manufacturing process and financial performance [1][2]. Financial Update - Total operating expenses for Q1 2025 were MNOK 22.2 [5]. - The net negative cash flow from operations was MNOK 36.0 [5]. - Proceeds from equity issuance amounted to MNOK 51.7, while net cash acquired from the business combination was MNOK 92.3, leading to a net increase in cash and cash equivalents of MNOK 108.0 during Q1 2025 [5]. - Cash and cash equivalents stood at MNOK 135.3 as of March 31, 2025 [5]. - A reverse share split was executed on March 31, 2025, resulting in 20,227,066 outstanding shares, each with a par value of NOK 1 [5]. Business Development - Zelluna successfully completed a business combination with Ultimovacs ASA and Zelluna Immunotherapy AS, along with a private placement that raised gross proceeds of MNOK 51.7 [5]. - The company has developed, scaled, and automated its proprietary manufacturing process for TCR-NK cell therapies, which allows for the production of hundreds of doses from a single batch, enhancing scalability and cost efficiency [5][6]. - The lead program targets MAGE-A4 for the treatment of various solid cancers, marking a significant innovation in the TCR-NK therapeutic field [6].

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) and multiple sclerosis (MS)Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus (SLE) support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025Company plans to advanc ...

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) and multiple sclerosis (MS)Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus (SLE) support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025Company plans to advanc ...

LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT / 14:30pm BST. A webcast of the fireside chat will be available ...

Group 1 - Mustang Bio, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement as per Nasdaq Listing Rule 5550(b)(1) [1][2] - The company previously satisfied the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing, thus meeting all Nasdaq Capital Market listing requirements [2] - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers, aiming to license or acquire technologies to fund research and development [3] Group 2 - Mustang Bio has partnered with leading medical institutions to advance CAR-T therapies [3] - The company's common stock is registered under the Securities Exchange Act of 1934 and it files periodic reports with the SEC [3]

Core Viewpoint - Mustang Bio, Inc. has exited its lease for a manufacturing facility in Worcester, Massachusetts, and divested certain fixed assets to AbbVie for $1.0 million, while relocating its corporate headquarters to Waltham, Massachusetts [1][2]. Group 1: Financial Implications - The termination of the lease is expected to result in approximately $2.0 million in cash expense savings over the next 24 months [2]. - The divestment of fixed assets to AbbVie Bioresearch Center Inc. was completed for a total of $1.0 million [1]. Group 2: Strategic Focus - The company remains committed to advancing its existing portfolio and plans to initiate a novel clinical trial with MB-109, targeting recurrent glioblastoma and high-grade astrocytomas in the second half of 2025 [3]. - MB-109 is a combination therapy that includes MB-101 (IL13Rα2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), aimed at enhancing the efficacy of CAR-T cell therapy by modifying the tumor microenvironment [4]. Group 3: Company Overview - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers, partnering with leading medical institutions to advance CAR-T therapies [5].